MYOKARDIA INC has a total of 96 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2014. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and chemical engineering are JIKAI BIOSCIENCES INC, ISOCURE BIOSCIENCES INC and CAPELLA THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | WIPO (World Intellectual Property Organization) | 9 | |
#3 | Australia | 7 | |
#4 | Israel | 7 | |
#5 | China | 6 | |
#6 | Singapore | 6 | |
#7 | EPO (European Patent Office) | 5 | |
#8 | Canada | 4 | |
#9 | Republic of Korea | 4 | |
#10 | Brazil | 3 | |
#11 | Chile | 2 | |
#12 | Costa Rica | 2 | |
#13 | Dominican Republic | 2 | |
#14 | EAPO (Eurasian Patent Organization) | 2 | |
#15 | Guatemala | 2 | |
#16 | Hong Kong | 2 | |
#17 | Mexico | 2 | |
#18 | Peru | 2 | |
#19 | Philippines | 2 | |
#20 | Tunisia | 2 | |
#21 | Taiwan | 2 | |
#22 | Ukraine | 2 | |
#23 | Argentina | 1 | |
#24 | Ecuador | 1 | |
#25 | Hungary | 1 | |
#26 | Japan | 1 | |
#27 | Morocco | 1 | |
#28 | Serbia | 1 | |
#29 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Chemical engineering | |
#4 | Environmental technology | |
#5 | Medical technology | |
#6 | Computer technology |
# | Name | Total Patents |
---|---|---|
#1 | Oslob Johan | 56 |
#2 | Song Yonghong | 54 |
#3 | Mcdowell Robert | 53 |
#4 | Aubele Danielle | 53 |
#5 | Sran Arvinder | 51 |
#6 | Evanchik Marc | 41 |
#7 | Kane Brian | 33 |
#8 | Fox Jonathan Charles | 31 |
#9 | Rodriguez Hector | 30 |
#10 | Anderson Robert | 29 |
Publication | Filing date | Title |
---|---|---|
WO2021011586A1 | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide | |
WO2020257609A1 | Diagnostics and treatments for cardiac disease | |
WO2020236736A1 | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide | |
US2020165247A1 | Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds | |
KR20200118025A | Pyrazole compound and preparation thereof | |
US2019269669A1 | 4-methylsulfonyl-substituted piperidine urea compounds | |
WO2019028360A1 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
WO2017044870A1 | Sensor for ventricular and outflow tract obstruction | |
SG11201705928XA | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
US2016176868A1 | Bicyclic-pyrimidinedione compounds | |
US2014378491A1 | Cycloalkyl-substituted pyrimidinedione compounds | |
SG11201510163TA | Pyrimidinedione compounds against cardiac conditions |